Kancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).
Read MoreKancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted 60 patients have been enrolled so far. The company...
Read MoreKancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer. As a result, Kancera has met...
Read MoreThis is a translation of the interim report published in swedish on Januaryt 19th
Read MoreDue to technical reasons this report was only published as a press release, but did not show up in the Finacial reports section on the Kancera web page. This is now corrected. First quarter in brief January – MarchFinancial...
Read MoreKancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.
Read MoreThis is a translation of a press release published in Swedish by Kancera AB (publ) on May 20, 2022.
Read MoreFirst quarter in brief January – MarchFinancial summary for the first quarter and the period January – March 2022· Net sales amounted to SEK 0 million (SEK 0.0 million).· R&D costs amounted to SEK 10,6 million (8,2 million).· Operating...
Read MoreThe year in brief October – DecemberFinancial summary for the fourth quarter Net sales amounted to SEK 0 million (0,0 million). R&D costs amounted to SEK 12,9 million (11,2 million). Operating profit for the fourth quarter amounted to SEK...
Read MoreKancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.
Read More